bionano GENOMICS

Bionano Genomics to Report First Quarter 2022 Financial Results and Host a Conference Call and Webcast on May 5, 2022

April 28, 2022

SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today announced that it will host a conference call and live webcast on Thursday, May 5th, 2022 at 4:30 p.m. Eastern Time to report financial results for the first quarter 2022 and to highlight recent corporate progress.

Conference Call & Webcast Details	
Date:	Thursday, May 5, 2022
Time:	4:30 p.m. Eastern Time
Toll Free:	1-800-239-9838
International:	1-720-543-0214
Conference ID:	2258678
Webcast:	https://edge.media-server.com/mmc/p/g8qft85w

To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. An archived version of the webcast will be available for replay in the Investors section of the Bionano website.

About Bionano Genomics

Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company's mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. For more information, visit www.bionanogenomics.com, www.lineagen.com or www.biodiscovery.com

CONTACTS

Company Contact: Erik Holmlin, CEO Bionano Genomics, Inc. +1 (858) 888-7610 eholmlin@bionanogenomics.com

Investor Relations: Amy Conrad Juniper Point +1 (858) 366-3243 amy@iuniper-point.com



Source: Bionano Genomics